Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of cancers and inflammation, announces that it has progressed discussions with the
It would appear that there is something of a land grab going on for Tirupati Graphite (TGR), the specialist graphite producer.
The AIM All-Share fell 0.7% over the week in the small-cap market. This was lower than the FTSE 100 which grew 1.3 percent.
Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells University of Auckland data
There was two for the price of one at pharma services group Open Orphan (ORPH), not only its hVIVO subsidiary signing a £5.7m contract with a specialist biotechnology company developing
Xtract Resources (XTR) continued its series of progress reports from its Bushranger copper-gold porphyry exploration project in New South Wales. Here the angled holes BRDD-21-013 and 014 of the Phase
Visit Share Talk TV for a chance to catch up with the previous weeks stock market interviews, and articles made public across multiple platforms including Share Talk, Vox Markets, Proactive Investors. We will expand
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 was effective in
We begin our weekly small company report with news that Yu Group PLC’s (LON:YU.) business update was well received by the market.
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces further progress and an update on clinical trial plans for SFX-01 in glioblastoma (“GBM”).
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
